Subscribe to our mailing list to receive regular email updates of ResPublica's work, upcoming events and recent blogs from the Disraeli Room.
Over the last few decades safe and effective new medical technologies have been widely welcomed by patients and health care professionals alike, and helped to transform life expectancy. Asthma inhalers are one of these major medical technology success stories – launching in the 1970’s they enabled the delivery of new active compounds to the lungs to fight asthma attacks in a highly portable unit.
The Coalition Government should be commended for its efforts to drive the life sciences agenda. After setting down an early statement of intent with the Strategy for UK life sciences, last year’s re-launch of the Office for Life Sciences, operating across the departments of business and health, signalled a clear intention to harness the potential of modern technology to create a health service fit for the 21st century.
Our health and social care systems are at a crossroads and of the wide-ranging health challenges currently facing the UK, one of the most unsettling issues is the persistent health inequalities experienced by populations across the North of England.
As we approach polling day, I believe the choice we are facing on the future of the NHS is becoming ever more clear. The choice is simple: between the focus of Jeremy Hunt and the Conservative Health team on supporting NHS leaders to improve the culture of care and transparency, promote patient empowerment and accelerate access to new treatments by unlocking the power of the NHS as a pioneer of medical innovation, and the depressing sight of Andy Burnham determined to ‘weaponise’ the NHS for partisan advantage.
42 Tavistock Street
London WC2E 7PB
020 3857 8310
For media enquiries, please email:
ResPublica is the trading name of The ResPublica Partnership Limited
Company Registration No: 11068087 England and Wales